艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABBV 艾伯维公司

盘后交易 11-21 18:45:33 EST

171.73

+3.97

+2.37%

盘后172.29

+0.56+0.33%

18:40 EST

最高172.46	最低166.92	成交量684.63万
今开168.59	昨收167.76	日振幅3.30%
总市值3,035亿	流通市值3,029亿	总股本17.67亿
成交额11.71亿	换手率0.39%	流通股本17.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":171.73,"timestamp":1732222800000,"preClose":167.76,"halted":0,"volume":6846332,"hourTrading":{"tag":"盘后","latestPrice":172.2899,"preClose":171.73,"latestTime":"18:40 EST","volume":434973,"amount":74697726.25161,"timestamp":1732232413082},"delay":0,"floatShares":1763993399,"shares":1767140323,"eps":2.869915,"marketStatus":"盘后交易","marketStatusCode":4,"change":3.97,"latestTime":"11-21 18:45:33 EST","open":168.59,"high":172.455,"low":166.92,"amount":1170702301.46732,"amplitude":0.032994,"askPrice":172.32,"askSize":100,"bidPrice":171.53,"bidSize":13,"shortable":3,"etf":0,"ttmEps":2.869915,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732237200000},"adr":0,"adjPreClose":167.76,"adrRate":0,"dividendRate":0.036103,"preHourTrading":{"tag":"盘前","latestPrice":167.84,"preClose":167.76,"latestTime":"09:28 EST","volume":3042,"amount":511815.98286,"timestamp":1732199338696},"postHourTrading":{"tag":"盘后","latestPrice":172.2899,"preClose":171.73,"latestTime":"18:40 EST","volume":434973,"amount":74697726.25161,"timestamp":1732232413082},"volumeRatio":0.84667,"optionData":{"bulkOrders":[{"symbol":"ABBV","call":false,"expireDate":1734670800000,"strike":"195.0","timestamp":1732215986274,"price":23.149999618530273,"volume":1840,"amount":4259600,"type":"-"},{"symbol":"ABBV","call":false,"expireDate":1734670800000,"strike":"195.0","timestamp":1732218909787,"price":23.149999618530273,"volume":1700,"amount":3935500,"type":"+"}]},"impliedVol":0.2295,"impliedVolPercentile":0.5556},"requestUrl":"/m/hq/s/ABBV","defaultTab":"news","newsList":[{"id":"2485419026","title":"艾伯维上涨1.25%，报169.865美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485419026","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485419026?lang=zh_cn&edition=full","pubTime":"2024-11-22 00:01","pubTimestamp":1732204885,"startTime":"0","endTime":"0","summary":"11月22日，艾伯维(ABBV)盘中上涨1.25%，截至00:01，报169.865美元/股，成交1.83亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。大事提醒：11月19日，艾伯维获富国银行上调目标价至195美元，最新评级Buy。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/22000145553102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0256863902.USD","IE00BVYPNV92.GBP","LU0203347892.USD","LU2089284900.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0211328371.USD","LU2237443895.HKD","LU2133065610.SGD","BK4550","LU0545039389.USD","BK4534","LU1291159041.SGD","LU0122379950.USD","LU0417517546.SGD","LU0820561818.USD","LU0211327993.USD","SG9999015978.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1934455863.HKD","LU0912757837.SGD","LU0943347566.SGD","LU0198837287.USD","SG9999015952.SGD","LU0203345920.USD","LU0949170772.SGD","SG9999003800.SGD","LU1496350171.SGD","LU0965509101.SGD","LU0795875169.SGD","LU1023059063.AUD","SG9999011175.SGD","IE00B3PB1722.GBP","ABBV","LU1267930490.SGD","LU2237443622.USD","LU0985320562.USD","BK4566","LU0310799852.SGD","IE00BDGV0183.EUR","IE0002141913.USD","LU2237443382.USD","SG9999015986.USD","LU1244550221.USD","SG9999015945.SGD","LU1732799900.SGD","LU1037948541.HKD"],"gpt_icon":0},{"id":"2483853674","title":"BUZZ-美股周报扣篮","url":"https://stock-news.laohu8.com/highlight/detail?id=2483853674","media":"路透中文","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483853674?lang=zh_cn&edition=full","pubTime":"2024-11-16 06:07","pubTimestamp":1731708428,"startTime":"0","endTime":"0","summary":"在特朗普挑选小肯尼迪领导美国最高卫生机构后，制药商  延续跌势。迪士尼DIS.N周涨幅达 16.2%，创 24 年来最佳表现。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"98146c4c4d0b693c9c527c5d7d922ebf","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4S3MM1KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","BK4504","LU0211327993.USD","LU1778281490.HKD","LU2458330169.SGD","LU1037948541.HKD","LU0889566641.SGD","IE00B4R5TH58.HKD","LU1989771016.USD","LU2237443382.USD","LU2264538146.SGD","DIS","LU0689472784.USD","LU1201861249.SGD","LU0130102774.USD","LU0553294199.USD","LU0114720955.EUR","LU0203347892.USD","MRNA","AMAT","LU0868494617.USD","LU0476273544.USD","IE00BQXX3F31.USD","LU2237443622.USD","LU1244550494.USD","BK4083","SG9999001424.SGD","SG9999002224.SGD","BK4147","BK4588","LU0545039389.USD","HD","LU0234572021.USD","LU1894683348.USD","LU0354030438.USD","LU0158827948.USD","ABBV","LU0354030511.USD","TPR","LU1894683264.USD","SCHW","BK4187","SG9999015986.USD","BK4518","LU2133065610.SGD","GD","LDOS","CPRI","BK4519","LU0648001328.SGD"],"gpt_icon":1},{"id":"2483536743","title":"BUZZ-美股周报扣篮","url":"https://stock-news.laohu8.com/highlight/detail?id=2483536743","media":"路透中文","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483536743?lang=zh_cn&edition=full","pubTime":"2024-11-16 06:07","pubTimestamp":1731708428,"startTime":"0","endTime":"0","summary":"在特朗普挑选小肯尼迪领导美国最高卫生机构后，制药商  延续跌势。迪士尼DIS.N周涨幅达 16.2%，创 24 年来最佳表现。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"98146c4c4d0b693c9c527c5d7d922ebf","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4T3MM1KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4518","IE00BQXX3F31.USD","BK4519","SG9999015986.USD","DIS","LU0354030438.USD","AMAT","LU1201861249.SGD","LU0868494617.USD","SG9999015945.SGD","ABBV","LU0114720955.EUR","LU1244550494.USD","SCHW","LU0211327993.USD","LU0648001328.SGD","CPRI","LU0203347892.USD","GD","LU1894683348.USD","LU0889566641.SGD","LU1037948541.HKD","HD","LU0689472784.USD","IE00B4R5TH58.HKD","LU0130102774.USD","LU2264538146.SGD","BK4187","LU0545039389.USD","BK4147","LU0476273544.USD","LU2237443622.USD","LU1778281490.HKD","MRNA","BK4504","LU2458330169.SGD","SG9999002224.SGD","LU0553294199.USD","LU1894683264.USD","SG9999001424.SGD","LU0234572021.USD","TPR","LU2133065610.SGD","BK4588","LDOS","BK4083","LU1989771016.USD","LU2237443382.USD","LU0158827948.USD","LU0354030511.USD"],"gpt_icon":1},{"id":"2483322372","title":"艾伯维下跌1.23%，报167.545美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322372","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483322372?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:34","pubTimestamp":1731681247,"startTime":"0","endTime":"0","summary":"11月15日，艾伯维(ABBV)开盘下跌1.23%，截至22:34，报167.545美元/股，成交1.44亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。大事提醒：11月12日，艾伯维获花旗下调目标价至215美元，最新评级Buy。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/15223445361702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1934455863.HKD","LU2237443465.HKD","LU1291159041.SGD","IE00BJJMRZ35.SGD","IE00BVYPNW00.USD","LU0985320562.USD","IE0009355771.USD","LU0456855351.SGD","LU0820561909.HKD","LU2237443382.USD","IE00BVYPNV92.GBP","LU1989772840.SGD","LU0234570918.USD","LU0882574055.USD","IE00BGHQF631.EUR","BK4533","LU1585245621.USD","LU1989772923.USD","LU1267930573.SGD","BK4581","ABBV","SG9999011175.SGD","LU0738911758.USD","LU0158827948.USD","LU1551013425.SGD","LU1934455277.USD","LU0861579265.USD","LU0310800379.SGD","LU0310799852.SGD","LU0211328371.USD","LU0661504455.SGD","SG9999015986.USD","IE00B4R5TH58.HKD","LU0128525929.USD","LU1037948897.HKD","LU1244550221.USD","LU1934455194.USD","SG9999015952.SGD","LU0912757837.SGD","IE0004445239.USD","SG9999015978.USD","LU0203345920.USD","IE00B3PB1722.GBP","LU0795875086.SGD","IE00BFTCPJ56.SGD","LU0029864427.USD","LU2237443622.USD","BK4588","IE00BDGV0183.EUR","IE0002141913.USD"],"gpt_icon":0},{"id":"2483082300","title":"美国研究综述-AMN 医疗保健服务公司、Chart Industries 公司、家得宝公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2483082300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483082300?lang=zh_cn&edition=full","pubTime":"2024-11-13 19:30","pubTimestamp":1731497406,"startTime":"0","endTime":"0","summary":"    路透11月13日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 AMN 医疗保健服务公司、Chart Industries 公司和家得宝公司。* 908 Devices Inc   ：Leerink Partners将目标价从12美元下调至4美元             * 908 Devices Inc   ：Leerink Partners 将其目标价从 \"跑赢大盘 \"下调至 \"跑输大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTLS","MASS","COLD","BLFS","CSX","DOCS","CRNX","AXSM","FDX","LU2133065610.SGD","BK4534","ACLX","BBIO","LU0128525689.USD","LU2106854487.HKD","BK4505","LU2249611893.SGD","HCSG","BMY","ALIT","DOX","BK4566","APA","CLF","SATS","LU2065731478.USD","COGT","BK4567","ABBV","CAVA","ALB","AESI","CHRW","DAY","COTY","HD","CCCS","AMN","ATLC","BHVN","BCAX","BLTE","CHGG","EWTX","LU0256863902.USD","AISP","CHH","DCOM","IRON","ARCH"],"gpt_icon":0},{"id":"2483078811","title":"揭开艾伯维87亿美金教训的真相","url":"https://stock-news.laohu8.com/highlight/detail?id=2483078811","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483078811?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:56","pubTimestamp":1731488201,"startTime":"0","endTime":"0","summary":"11月11日，艾伯维宣布，去年底斥资87亿美元收购Cerevel得到的“王牌项目” emraclidine，未能在两项针对精神分裂症的II期研究中达到预期终点，这为其未来蒙上阴影。消息一出，艾伯维股价暴跌12.57%，一夜之间市值蒸发400多亿美元。快、准、狠，预示了艾伯维应对专利悬崖的决心。艾伯维却十分看好Cerevil。次日，艾伯维便豪爽的表示愿意考虑提高报价，并要求先安排双方CEO会谈。但仅仅一年之后，emraclidine临床失败，只剩下艾伯维的“窒息”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113165741a2334d9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113165741a2334d9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","LU0708994859.HKD","IE00BVYPNV92.GBP","LU0256863811.USD","LU0122379950.USD","BK4581","BK4588","LU0203345920.USD","LU0234570918.USD","LU0965509101.SGD","IE0004445239.USD","LU0689472784.USD","IE00BVYPNW00.USD","ABBV","LU0211327993.USD","LU0882574055.USD","LU0553294199.USD","LU0912757837.SGD","BK4566","LU0128525929.USD","LU0170899867.USD","IE0009355771.USD","LU0198837287.USD","LU0417517546.SGD","LU0965508806.USD","BK4533","LU0545039389.USD","LU0820561818.USD","LU1003077747.HKD","IE00BJJMRZ35.SGD","LU0985320562.USD","IE00BSNM7G36.USD","LU0203347892.USD","LU0029864427.USD","LU0661504455.SGD","LU0738911758.USD","BK4550","LU0949170772.SGD","LU0310799852.SGD","LU0158827948.USD","LU1023059063.AUD","BK4139","IE00BGHQF631.EUR","LU0456855351.SGD","IE00B42XCP33.USD","LU0310800379.SGD","LU0211328371.USD","IE00B4R5TH58.HKD","LU0795875169.SGD","BK4559"],"gpt_icon":0},{"id":"2483001254","title":"“精分”领域8成新药不活跃，艾伯维新药未达终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001254","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483001254?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:31","pubTimestamp":1731468719,"startTime":"0","endTime":"0","summary":"11月11日，艾伯维宣布其用于治疗精神病症状急性加重的精神分裂症新药Emraclidine的两项EMPOWER试验未达到其主要终点，即与安慰剂相比，其在改善PANSS总分方面没有统计学上的显著差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113114439a2324e03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113114439a2324e03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0882574055.USD","LU0203347892.USD","LU0211328371.USD","LU0211327993.USD","LU0820561909.HKD","LU0965509101.SGD","LU1023059063.AUD","LU0256863811.USD","IE00BDGV0183.EUR","IE0009355771.USD","BK4559","LU0310800379.SGD","LU0661504455.SGD","LU0861579265.USD","LU0456855351.SGD","LU0029864427.USD","LU0965509010.AUD","LU0122379950.USD","IE00BJT1NW94.SGD","LU0912757837.SGD","IE00BVYPNW00.USD","IE00B4R5TH58.HKD","LU0820561818.USD","LU0234572021.USD","LU0985320562.USD","IE00BFTCPJ56.SGD","LU0417517546.SGD","LU0738911758.USD","ABBV","BK4139","IE00B42XCP33.USD","LU0256863902.USD","BK4533","BK4585","LU0203345920.USD","LU0795875086.SGD","LU0795875169.SGD","LU1003077747.HKD","LU0198837287.USD","LU0965508806.USD","LU0114720955.EUR","LU0170899867.USD","IE00BJJMRZ35.SGD","LU0234570918.USD","LU0965509283.SGD","LU0708994859.HKD","LU0689472784.USD","LU0158827948.USD","IE00BVYPNV92.GBP","BK4534"],"gpt_icon":0},{"id":"2483060896","title":"87亿美元打水漂？艾伯维Emraclidine精神分裂症2期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2483060896","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483060896?lang=zh_cn&edition=full","pubTime":"2024-11-13 07:31","pubTimestamp":1731454305,"startTime":"0","endTime":"0","summary":"11月11日，艾伯维宣布，以90亿美元收购 Cerevel的核心药物EMPOWER在两项针对精神分裂症患者的 II 期EMPOWER-1和EMPOWER-2临床试验中失败。入组患者均按每天服用一次emraclidine，测量6周的PANSS影响。在Cobenfy已经获批上市的情况下，Emraclidine的临床试验失败对AbbVie来说是一个重大打击，同时也可能改变精神分裂症治疗市场的竞争格局，对于BMS来说，相当于市场预期消除了Cobenfy最大的竞争对手，并可能将峰值销售预期推到一致预期40亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113074203abbb3ff1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113074203abbb3ff1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BGHQF631.EUR","BK4563","LU0256863811.USD","IE00B2B36J28.USD","IE00BDGV0183.EUR","LU0211328371.USD","LU0795875169.SGD","LU0310800379.SGD","LU0965509101.SGD","LU0234572021.USD","LU0198837287.USD","IE00B42XCP33.USD","IE00BJT1NW94.SGD","PAM","LU0310799852.SGD","LU0128525929.USD","LU0861579265.USD","LU0170899867.USD","LU0203347892.USD","LU0965509010.AUD","BK4559","LU0708994859.HKD","LU0456855351.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU0949170772.SGD","IE00B4R5TH58.HKD","LU0943347566.SGD","LU0965509283.SGD","LU0738911758.USD","BK4081","LU0689472784.USD","LU0795875086.SGD","LU0114720955.EUR","EMPW.U","LU0985320562.USD","IE0009355771.USD","LU0029864427.USD","BK4588","LU1023059063.AUD","IE00BJJMRZ35.SGD","BK4581","IE0002141913.USD","ABBV","BK4533","LU0545039389.USD","LU0553294199.USD","IE00BFTCPJ56.SGD","IE00B3PB1722.GBP","BK4139"],"gpt_icon":0},{"id":"2483178053","title":"艾伯维下跌1.22%，报172.31美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483178053","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483178053?lang=zh_cn&edition=full","pubTime":"2024-11-13 03:27","pubTimestamp":1731439627,"startTime":"0","endTime":"0","summary":"11月13日，艾伯维(ABBV)盘中下跌1.22%，截至03:27，报172.31美元/股，成交9.97亿美元。财务数据显示，截至2024年09月30日，艾伯维收入总额412.32亿美元，同比增长3.04%；归母净利润43.0亿美元，同比增长6.41%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/13032745223505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["IE00B4R5TH58.HKD","IE00BVYPNV92.GBP","IE0004445239.USD","LU0820561909.HKD","LU0965508806.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU0417517546.SGD","LU0661504455.SGD","LU0203345920.USD","BK4550","LU0234572021.USD","LU0985320562.USD","LU0310799852.SGD","LU0211327993.USD","LU0949170772.SGD","IE00BJT1NW94.SGD","IE00B3PB1722.GBP","IE00B42XCP33.USD","LU0689472784.USD","IE0009355771.USD","LU1023059063.AUD","LU0158827948.USD","IE00BVYPNW00.USD","LU0234570918.USD","LU0553294199.USD","LU0310800379.SGD","LU1003077747.HKD","LU0795875086.SGD","IE00BSNM7G36.USD","LU0708994859.HKD","LU0211328371.USD","LU0820561818.USD","LU0128525929.USD","LU0861579265.USD","LU0882574055.USD","LU0738911758.USD","BK4533","LU0795875169.SGD","LU0965509010.AUD","ABBV","IE00BFTCPJ56.SGD","BK4534","BK4559","IE0002141913.USD","LU0965509101.SGD","IE00B2B36J28.USD","LU0203347892.USD","LU0029864427.USD","LU0545039389.USD"],"gpt_icon":0},{"id":"2482773144","title":"美国研究综述-Cable One、Neurogene、Topbuild","url":"https://stock-news.laohu8.com/highlight/detail?id=2482773144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482773144?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:43","pubTimestamp":1731404607,"startTime":"0","endTime":"0","summary":"    路透11月12日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cable One、Neurogene 和 Topbuild。要闻 * Cable One Inc   ：摩根大通将目标价从480美元下调至470美元 * Hudson Pacific Properties Inc   ：杰富瑞将目标价从 \"买入 \"下调至 \"持有  * Neurogene Inc   ：Leerink Partners将目标价从45美元上调至72美元 * Rapt Therapeutics Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU","EOG","LU1003077747.HKD","DOCS","GPMT","JLL","BK4123","EYPT","ARMK","DAL","ARDT","ARCB","HPP","CMTG","AIZ","CDE","CTVA","LU0256331488.USD","BLD","BMY","LU0648001328.SGD","LU2242652126.USD","AL","BK4101","CABO","BAX","APD","FTRE","ABBV","AEO","ALB","LU0211328371.USD","HMN","IE00BBT3K403.USD","BILL","BLMN","DB","FTNT","DKNG","ATLC","ADSK","CACI","AIG","IMXI","AGL","CCL","LU0070302665.USD","AFG"],"gpt_icon":1},{"id":"2482773045","title":"艾伯维大跌！","url":"https://stock-news.laohu8.com/highlight/detail?id=2482773045","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482773045?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:24","pubTimestamp":1731403492,"startTime":"0","endTime":"0","summary":"周一收盘，艾伯维股价暴跌超过12%，市值损失超过300亿美元。至于下跌的原因，则与艾伯维宣布失败的两项临床试验有关。根据艾伯维2023财报，2023年艾伯维所有上市产品共营收543.18亿美元，同比增长6.4%。综合来看，此次II期研究失利的Emraclidine的确是艾伯维神经科学板块的重要管线之一，被寄予厚望。前后两个消息的碰撞下，就在艾伯维周一大跌的同时，BMS股价却悄然上涨约12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112173114abb99389&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112173114abb99389&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0943347566.SGD","IE0002141913.USD","LU0198837287.USD","LU0820561909.HKD","LU0965509283.SGD","LU0861579265.USD","LU1003077747.HKD","BK4559","LU0234570918.USD","LU0965509010.AUD","LU0965509101.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0689472784.USD","LU0912757837.SGD","IE00BJT1NW94.SGD","LU0553294199.USD","LU0795875086.SGD","LU0114720955.EUR","LU0820561818.USD","LU0965508806.USD","LU0128525929.USD","LU0661504455.SGD","BK4581","IE00BDGV0183.EUR","LU0708994859.HKD","BK4534","IE00BFTCPJ56.SGD","BK4139","BK4588","LU0545039389.USD","IE00BVYPNV92.GBP","LU0234572021.USD","LU0456855351.SGD","LU0256863811.USD","LU0417517546.SGD","LU0122379950.USD","LU0158827948.USD","ABBV","LU0029864427.USD","LU0310800379.SGD","IE00B3PB1722.GBP","LU0256863902.USD","LU0170899867.USD","IE00BJJMRZ35.SGD","LU0203345920.USD","LU0738911758.USD","BK4566","EMPW.U","IE0009355771.USD"],"gpt_icon":0},{"id":"2482715620","title":"大跌12%，艾伯维精神分裂症药物研究失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2482715620","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482715620?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:25","pubTimestamp":1731378301,"startTime":"0","endTime":"0","summary":"11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。2023年12月，艾伯维以87亿美元收购了Cerevel Therapeutics及其后期资产Emraclidine。它通过选择性地调节M4受体来减少多巴胺信号，而不需要阻断D2受体，这可能减少现有抗精神病药物的副作用。Emraclidine的临床试验失败对AbbVie来说是一个重大打击，受此消息的影响，艾伯维股价大跌超12%，市值蒸发约 400 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0553294199.USD","LU0965509010.AUD","LU0029864427.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0417517546.SGD","LU0882574055.USD","LU0198837287.USD","LU0985320562.USD","LU0738911758.USD","IE00B2B36J28.USD","LU0861579265.USD","IE00BVYPNW00.USD","BK4139","LU0256863902.USD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU0203345920.USD","LU0949170772.SGD","LU0661504455.SGD","IE0009355771.USD","LU0820561909.HKD","LU0122379950.USD","ABBV","LU1003077747.HKD","IE00BGHQF631.EUR","LU0158827948.USD","BK4533","LU0545039389.USD","LU0795875169.SGD","LU0256863811.USD","BK4585","IE00B42XCP33.USD","LU0310800379.SGD","LU0965509101.SGD","LU0820561818.USD","LU0170899867.USD","LU0310799852.SGD","IE00BJJMRZ35.SGD","BK4563","BK4581","IE00B3PB1722.GBP","IE00BDGV0183.EUR","LU0211328371.USD","BK4566","LU0965508806.USD","PAM","LU0211327993.USD","BK4559"],"gpt_icon":0},{"id":"2482731161","title":"BUZZ-券商观点：艾伯维精神分裂症药物失败 \"将留下印记","url":"https://stock-news.laohu8.com/highlight/detail?id=2482731161","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482731161?lang=zh_cn&edition=full","pubTime":"2024-11-11 23:53","pubTimestamp":1731340387,"startTime":"0","endTime":"0","summary":"11月11日 -  ** 艾伯维ABBV.N称， ，其通过87亿美元收购Cerevel Therapeutics获得的一种实验性精神分裂症药物未能通过两项中期研究，导致该制药商股价暴跌12.5%。** Piper Sandler 称负面结果 \"将留下印记\"。** 券商预计投资者将重新关注艾伯维通过内部研发努力或外部业务开发引入更多增长动力的能力。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL4T3MI16H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU1670710588.SGD","LU0708994859.HKD","IE00BVYPNV92.GBP","LU0122379950.USD","BK4588","LU0234570918.USD","LU0868494617.USD","BK4007","IE0004445239.USD","LU0225284248.USD","LU1074936037.SGD","ABBV","LU0211327993.USD","LU0882574055.USD","LU0306807586.USD","LU0553294199.USD","LU0128525929.USD","LU0912757837.SGD","LU0170899867.USD","LU0965508806.USD","LU1571399168.USD","LU1261432733.SGD","LU0965509283.SGD","LU0256863902.USD","BK4585","LU1585245621.USD","LU0545039389.USD","LU0820561818.USD","LU1989771016.USD","LU2242652126.USD","LU0203347892.USD","LU0661504455.SGD","LU0861579265.USD","LU0949170772.SGD","LU0310799852.SGD","LU0795875086.SGD","LU0158827948.USD","LU1023059063.AUD","LU1093756168.USD","LU0985481810.HKD","IE00B42XCP33.USD","BK4534","BMY","LU0310800379.SGD","IE00BFTCPJ56.SGD","LU0211328371.USD","IE00B4R5TH58.HKD","LU0795875169.SGD","BK4559"],"gpt_icon":0},{"id":"2482973953","title":"艾伯维(ABBV)跌12.22% 两项治疗精神分裂症药物中期试验未达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2482973953","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482973953?lang=zh_cn&edition=full","pubTime":"2024-11-11 23:28","pubTimestamp":1731338913,"startTime":"0","endTime":"0","summary":"金吾财讯 | 艾伯维(ABBV)股价下行，截至发稿，跌12.22%，报175.18美元。该股股价出现三年来最大跌幅，此前该公司治疗精神分裂症药物的两项中期试验未能达到其主要目标，这对该公司今年早些时候斥资 87 亿美元收购 Cerevel Therapeutics 造成了打击。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OTg4YTUxMDE3ODY5MDkyNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTg4YTUxMDE3ODY5MDkyNDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"281854","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","LU0545039389.USD","IE00BSNM7G36.USD","LU0234570918.USD","LU0256863902.USD","BK4585","IE00BGHQF631.EUR","LU0029864427.USD","LU0211328371.USD","IE00BFTCPJ56.SGD","LU0211327993.USD","LU0965509283.SGD","LU0820561909.HKD","LU0965509010.AUD","LU0170899867.USD","LU0122379950.USD","LU0128525929.USD","LU0965509101.SGD","BK4566","IE00BDGV0183.EUR","ABBV","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","BK4533","LU0820561818.USD","IE00BVYPNW00.USD","BK4588","BK4581","LU0689472784.USD","IE0009355771.USD","LU0310799852.SGD","LU0553294199.USD","LU0965508806.USD","LU0456855351.SGD","LU0738911758.USD","LU0949170772.SGD","IE00B42XCP33.USD","LU0417517546.SGD","IE00BJJMRZ35.SGD","LU0882574055.USD","BK4550","LU0310800379.SGD","IE0004445239.USD","LU0912757837.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0661504455.SGD","IE00BVYPNV92.GBP","LU0943347566.SGD"],"gpt_icon":0},{"id":"2482735862","title":"精神分裂症药物研究失败 艾伯维公司大跌超12% 施贵宝上涨13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482735862","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482735862?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:51","pubTimestamp":1731336673,"startTime":"0","endTime":"0","summary":"周一，艾伯维公司(ABBV.US)大幅低开，截至发稿，大跌超12%，报174.21美元。消息面上，艾伯维公司表示，最近收购的治疗精神分裂症的艾玛克拉丁候选药物未能在一对中期研究中达到关键目标，艾玛克拉丁的2期研究未达到其主要终点，在第六周未出现患有这种心理健康障碍患者症状严重程度的改善的统计学显著性。公司表示，仍在分析研究数据，以确定下一步的步骤。值得注意的是，施贵宝(BMY.US)却上涨13%，创下2006年3月以来的最大涨幅。分析人士称，这支股票可能是在对艾伯维以上消息做出回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111225540a22cf0c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111225540a22cf0c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BDGV0183.EUR","IE00BVYPNV92.GBP","LU0170899867.USD","BK4588","IE0004445239.USD","LU0820561909.HKD","LU0965508806.USD","IE00BJJMRZ35.SGD","LU1989771016.USD","LU2125154778.USD","BK4566","LU0417517546.SGD","LU2360032135.SGD","BMY","LU0234572021.USD","LU0237698245.USD","LU1571399168.USD","LU0211327993.USD","BK4581","LU0949170772.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU0321505868.SGD","LU0456855351.SGD","IE00BVYPNW00.USD","LU0234570918.USD","LU2125154935.USD","LU0553294199.USD","LU2242646821.SGD","LU0310800379.SGD","LU0795875086.SGD","LU0912757837.SGD","LU0985481810.HKD","LU1291159041.SGD","LU0820561818.USD","LU0128525929.USD","LU0861579265.USD","LU1093756325.SGD","LU0225284248.USD","LU1670710588.SGD","LU0738911758.USD","BK4533","LU0795875169.SGD","ABBV","LU0965509101.SGD","IE00B2B36J28.USD","LU1093756168.USD","LU0029864427.USD","LU0545039389.USD","LU1261432733.SGD"],"gpt_icon":0},{"id":"1144919254","title":"精神分裂症药物研究失败，艾伯维公司大跌，竞争对手施贵宝大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1144919254","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144919254?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:43","pubTimestamp":1731336187,"startTime":"0","endTime":"0","summary":"创下2006年3月以来的最大涨幅。","market":"us","thumbnail":"https://static.tigerbbs.com/81195b8f1f56d11a7f44f9f951806b19","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/81195b8f1f56d11a7f44f9f951806b19"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"精神分裂症药物研究失败，艾伯维公司大跌，竞争对手施贵宝大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","BMY"],"gpt_icon":0},{"id":"2482733326","title":"美股异动 | 精神分裂症药物研究失败 艾伯维公司(ABBV.US)大跌超12% 施贵宝(BMY.US)上涨13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482733326","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482733326?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:40","pubTimestamp":1731336004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，艾伯维公司(ABBV.US)大幅低开，截至发稿，大跌超12%，报174.21美元。消息面上，艾伯维公司表示，最近收购的治疗精神分裂症的艾玛克拉丁候选药物未能在一对中期研究中达到关键目标，艾玛克拉丁的2期研究未达到其主要终点，在第六周未出现患有这种心理健康障碍患者症状严重程度的改善的统计学显著性。公司表示，仍在分析研究数据，以确定下一步的步骤。值得注意的是，施贵宝(BMY.US)却上涨13%，创下2006年3月以来的最大涨幅。分析人士称，这支股票可能是在对艾伯维以上消息做出回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2125154778.USD","LU0225284248.USD","LU1585245621.USD","LU2242652126.USD","IE00BJT1NW94.SGD","LU0306807586.USD","IE00B4R5TH58.HKD","BK4139","LU2133065610.SGD","LU0545039389.USD","LU1718418525.SGD","LU0861579265.USD","LU0310800379.SGD","LU1093756325.SGD","BK4566","BMY","LU0256863811.USD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU1003077747.HKD","LU0321505439.SGD","LU0234570918.USD","LU2242646821.SGD","LU0965509283.SGD","IE00B2B36J28.USD","LU0114720955.EUR","LU2360032135.SGD","IE00BVYPNV92.GBP","LU0965509101.SGD","LU0310799852.SGD","BK4532","LU1670711040.USD","BK4534","LU0882574055.USD","LU0708994859.HKD","LU1571399168.USD","LU1670711123.USD","IE0009355771.USD","ABBV","BK4585","IE00B3PB1722.GBP","LU0795875169.SGD","LU1989771016.USD","LU0122379950.USD","IE0002141913.USD","BK4007","LU0211327993.USD","LU0306806265.USD","LU1261432733.SGD"],"gpt_icon":0},{"id":"2482738821","title":"艾伯维公司股价重挫10.78% 市值跌339.07亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482738821","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482738821?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:31","pubTimestamp":1731335502,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日22时31分，艾伯维公司股票出现异动，股价快速跳水10.78%。截至发稿，该股报177.99美元/股，成交量117.807万股，换手率0.07%，振幅0.29%。最近的财报数据显示，该股实现营业收入144.60亿美元，净利润15.51亿美元，每股收益0.88美元，毛利102.67亿美元，市盈率62.02倍。机构评级方面，在所有32家参与评级的机构中，69%的券商给予买入建议，31%的券商给予持有建议，无券商给予卖出建议。艾伯维公司股票所在的制药行业中，整体跌幅为0.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111122314295be103a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111122314295be103a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0203347892.USD","LU0456855351.SGD","LU0203345920.USD","IE00BFTCPJ56.SGD","BK4585","LU0708994859.HKD","LU0122379950.USD","LU0985320562.USD","LU0943347566.SGD","LU0553294199.USD","LU1023059063.AUD","LU0158827948.USD","IE00B42XCP33.USD","BK4550","LU0965508806.USD","IE00BVYPNV92.GBP","BK4581","LU0965509101.SGD","IE00BSNM7G36.USD","LU0256863811.USD","BK4566","IE00B2B36J28.USD","LU0128525929.USD","LU0310800379.SGD","LU0689472784.USD","IE0002141913.USD","LU0198837287.USD","LU0417517546.SGD","LU0661504455.SGD","LU0234572021.USD","LU0820561909.HKD","IE00BDGV0183.EUR","LU0029864427.USD","LU0861579265.USD","LU0949170772.SGD","LU0234570918.USD","ABBV","IE0009355771.USD","LU0545039389.USD","BK4534","BK4588","LU1003077747.HKD","IE00B3PB1722.GBP","LU0114720955.EUR","LU0795875169.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","BK4559","LU0170899867.USD","LU0211328371.USD"],"gpt_icon":0},{"id":"2482782037","title":"BUZZ-精神分裂症药物中期研究失败，艾伯维业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2482782037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482782037?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:08","pubTimestamp":1731334116,"startTime":"0","endTime":"0","summary":"** 竞争对手百时美施贵宝  的股价盘前上涨13%至61.13美元 ** BMY的药物Cobenfy是一种治疗精神分裂症的新型药物，已于9月份获得美国FDA批准。** 精神分裂症是一种导致持续妄想和幻觉的疾病，严重影响患者对现实的感知能力 ** 截至上次收盘，ABBV 累计上涨约 29%，BMY 累计上涨 5.5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BVYPNW00.USD","LU0225284248.USD","LU1585245621.USD","LU2242652126.USD","BK4139","LU2133065610.SGD","LU0545039389.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","LU1718418525.SGD","LU0861579265.USD","LU1093756325.SGD","LU0321505868.SGD","BMY","LU0256863811.USD","LU0949170772.SGD","LU0738911758.USD","LU0985320562.USD","LU0170899867.USD","LU1003077747.HKD","LU0256863902.USD","LU0029864427.USD","LU0321505439.SGD","LU0943347566.SGD","LU1074936037.SGD","LU0234570918.USD","LU0234572021.USD","BK4559","LU0965509283.SGD","IE00B2B36J28.USD","LU0114720955.EUR","LU0912757837.SGD","LU2360032135.SGD","LU0417517546.SGD","LU0965509010.AUD","LU1430594728.SGD","LU0310799852.SGD","LU1670711040.USD","BK4534","LU0708994859.HKD","LU0553294199.USD","ABBV","LU0128525929.USD","BK4585","LU1670710588.SGD","LU0965508806.USD","LU1670710661.SGD","IE00BGHQF631.EUR","BK4007"],"gpt_icon":0},{"id":"1180703652","title":"异动解读 | 艾伯维公司试验性精神分裂症药物研发失利 股价暴跌近14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180703652","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180703652?lang=zh_cn&edition=full","pubTime":"2024-11-11 21:38","pubTimestamp":1731332306,"startTime":"0","endTime":"0","summary":"艾伯维公司旗下试验性精神分裂症药物未能达到两项中期试验的主要目标,导致公司股价在今天盘前就大跌近14%。\n\n作为一家主攻抗癌以及免疫类疾病药物研发的大型生物制药公司,这一消息无疑让业界和投资人大跌眼镜。新药研发是艾伯维公司未来长期增长的核心动力之一,此次重磅新品失利打击了大家对该公司前景的信心。\n\n精神分裂症药物属于一个利润丰厚的全球市场,按照预期如果该药物一旦上市将为艾伯维公司贡献数十亿美元年收入。现在进展受阻,市场自然会对公司未来盈利能力产生质疑,从而体现在股价暴跌上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 艾伯维公司试验性精神分裂症药物研发失利 股价暴跌近14%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABBV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":-0.1007},{"period":"3month","weight":-0.1457},{"period":"6month","weight":0.0681},{"period":"1year","weight":0.2093},{"period":"ytd","weight":0.0825}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.023334},{"month":2,"riseRate":0.833333,"avgChangeRate":0.030818},{"month":3,"riseRate":0.75,"avgChangeRate":0.006329},{"month":4,"riseRate":0.666667,"avgChangeRate":0.015725},{"month":5,"riseRate":0.666667,"avgChangeRate":0.006183},{"month":6,"riseRate":0.5,"avgChangeRate":0.00974},{"month":7,"riseRate":0.5,"avgChangeRate":0.01182},{"month":8,"riseRate":0.5,"avgChangeRate":-0.0014},{"month":9,"riseRate":0.5,"avgChangeRate":0.007813},{"month":10,"riseRate":0.666667,"avgChangeRate":0.012917},{"month":11,"riseRate":0.75,"avgChangeRate":0.059268},{"month":12,"riseRate":0.727273,"avgChangeRate":0.032678}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}